Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of the American Academy of Dermatology

Topics

Immunology

Pathology

Physiology

Dermatology

Internal Medicine

Surgery

Gastroenterology

Medicine

Immunology

Pathology

Physiology

Dermatology

Show all topics

DOI

10.1016/j.jaad.2018.01.016

License

CC-BY-NC-ND

Other Formats

PDF